From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Comparing and Contrasting Predictive Biomarkers for Immunotherapy and Targeted Therapy of NSCLC

Last Updated: Thursday, July 22, 2021

The development of immune checkpoint inhibitors has dramatically altered the NSCLC treatment landscape. The authors compare and contrast the clinical development of immunotherapy and oncogene-directed therapy for NSCLC, focusing on the role of predictive biomarkers.

Nature Reviews Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement